"An Open-label, Multiple Ascending Dose Study to Determine the Maximum Tolerated Dose of R1530 in Patients With Advanced Solid Tumors."

Inclusion Criteria:

- adult patients, >=18 years of age;

- cancer not amenable to curative treatment (ie advanced and/or metastatic);

- measurable or evaluable disease;

- adequate cardiac, hepatic and renal function.

Exclusion Criteria:

- patients with known CNS metastases;

- serious cardiovascular illness or other medical conditions;

- prior chemotherapy, radiotherapy or immunotherapy within 28 days of start of
treatment , or hormone therapy within 14 days of start of treatment;

- inability to swallow oral medications, or impaired gastrointestinal absorption.